Please provide your email address to receive an email when new articles are posted on . 42.6% of patients filled a SABA prescription 30 days before an exacerbation, and 61.4% did so within 30 days ...

Asthma is an umbrella diagnosis covering a number of heterogeneous inflammatory pathways. In the past, excessive T-helper cell type 2 (Th2) response and immunoglobulin E (IgE) sensitivity were thought ...

It is administered as twice-daily, fixed-dose therapy in a pressurized metered-dose inhaler (pMDI) using a particle formulation designed for deep lung deposition. Chiesi’s robust clinical trial ...

In the WAYFINDER trial, tezepelumab reduced oral corticosteroid use in patients with severe asthma, with well-controlled asthma rising from 3% to 27% after 1 year.

Nektar Therapeutics (NASDAQ:NKTR) shares climbed 3.6% on Monday after the biotech firm unveiled encouraging new data showing ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

The wheezing. The coughing. The extreme and sudden shortness of breath. These are symptoms that are attached to asthma, which is a surprisingly common condition. According to the Asthma and Allergy ...

Please provide your email address to receive an email when new articles are posted on . Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with ...

Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug ...